Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.

The Journal of clinical investigation - 1 Dec 2004

Silk Jonathan D, Hermans Ian F, Gileadi Uzi, Chong Tsung Wen, Shepherd Dawn, Salio Mariolina, Mathew Bini, Schmidt Richard R, Lunt Sarah Jane, Williams Kaye J, Stratford Ian J, Harris Adrian L, Cerundolo Vincenzo

Abstract excerpt

Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD1
Share to Antigens, CD1d

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-2 Antigen

Share to Cell Separation

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Mice, Inbred C3H

Share to Toll-Like Receptors

Source

Open in PubMed Open full text

Identifiers

PMID: 15599405
DOI: 10.1172/JCI22046
PMCID: PMC535067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15599405-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.PMID 15599405Read ↗

Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.Semantic proximity Read ↗

Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunitySemantic proximity Read ↗

Immunotherapy with ligands of natural killer T cells.Semantic proximity Read ↗

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.Semantic proximity Read ↗

CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.Semantic proximity Read ↗

Adjuvant and immunomodulatory potential of <i>in vivo</i> Natural Killer T (NKT) activation by NKTT320Semantic proximity Read ↗

Development of a novel mechanism-based glycolipid adjuvant for vaccinationSemantic proximity Read ↗

Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice.Semantic proximity Read ↗

Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.Semantic proximity Read ↗

Reconstitution models to evaluate natural killer T cell function in tumor control.Semantic proximity Read ↗

Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of α-galactosylceramide in vivo.Semantic proximity Read ↗

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.